際際滷

際際滷Share a Scribd company logo

Nesina

Download as PPTX, PDF
Aparna Parayil
Aparna Parayil

Nesina is a dipeptidyl peptidase 4-inhibitor approved in 2013 for treating type 2 diabetes. It works by increasing incretin hormone levels to reduce fasting and postprandial glucose levels. Common side effects include hypoglycemia and nasopharyngitis. It is metabolized in the liver with a half-life of 21 hours and is excreted primarily in urine. Patients should be monitored for signs of pancreatitis and caution is needed with renal impairment or abnormal liver function tests.

1 of 7
Download to read offline
DRUG FOR THE WEEK NESINA
NESINA Therapeutic class:-Dipeptidyl peptidase 4-inhibitor Generic name:-Alogliptin benzoate Trade name:-Nesina FDA Approved date :- 26 January 2013
Company name:- Takeda Cost:- 25 mg (Rs.209.40) ,12.5 mg(Rs.112.20), 6.25mg (Rs.60.40) Indications:- Type 2 diabetes mellitus Dosage:- Adults:- Usual- 25mg- qd Renal Impairment: Moderate : 12.5mg qd . End-Stage Renal Disease/severe: 6.25mg qd. Pregnancy:- Category B
Mechanism of action:- It increases the activation of incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting postprandial glucose concentrations . Pharmacokinetics:- Absorption:- Absolute bioavailability (100%) Distribution:- 20% plasma protein binding Metabolism:- hepatic metabolism occurs Elimination:- Feces (13%), Urine (76%), T1/2=21 hrs
Adverse drug reactions:- Hypoglycemia Nasopharyngitis Throbbing headache Drug interactions:- Bexarotene Gatifloxacin
Warning and Precautions:- Not for use in type 1 diabetes, diabetes ketoacidosis D/c if pancreatitis is suspected Use with caution in patients with abnormal LFTs Patient counselling:- Avoid alcohol consumption If a dose is missed not to take a double dose Inform signs / symptoms of pancreatitis Instruct to inform physician if unusual symptom develops or if a symptom persists/worsens.
Nesina

More Related Content

Nesina

  • 1. DRUG FOR THE WEEK NESINA
  • 2. NESINA Therapeutic class:-Dipeptidyl peptidase 4-inhibitor Generic name:-Alogliptin benzoate Trade name:-Nesina FDA Approved date :- 26 January 2013
  • 3. Company name:- Takeda Cost:- 25 mg (Rs.209.40) ,12.5 mg(Rs.112.20), 6.25mg (Rs.60.40) Indications:- Type 2 diabetes mellitus Dosage:- Adults:- Usual- 25mg- qd Renal Impairment: Moderate : 12.5mg qd . End-Stage Renal Disease/severe: 6.25mg qd. Pregnancy:- Category B
  • 4. Mechanism of action:- It increases the activation of incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting postprandial glucose concentrations . Pharmacokinetics:- Absorption:- Absolute bioavailability (100%) Distribution:- 20% plasma protein binding Metabolism:- hepatic metabolism occurs Elimination:- Feces (13%), Urine (76%), T1/2=21 hrs
  • 5. Adverse drug reactions:- Hypoglycemia Nasopharyngitis Throbbing headache Drug interactions:- Bexarotene Gatifloxacin
  • 6. Warning and Precautions:- Not for use in type 1 diabetes, diabetes ketoacidosis D/c if pancreatitis is suspected Use with caution in patients with abnormal LFTs Patient counselling:- Avoid alcohol consumption If a dose is missed not to take a double dose Inform signs / symptoms of pancreatitis Instruct to inform physician if unusual symptom develops or if a symptom persists/worsens.